- Approved
- Type
- New molecular entity
- FDA-approved use
- To treat a severe form of Niemann-Pick disease type CWording from FDA's list of novel approvals.
At a glance
Lembaz (adrabetadex) is approved by the FDA to treat a severe form of Niemann-Pick disease type C. The supplied sources do not report the efficacy result of the pivotal trial, so no effect size can be given here. It has no boxed warning.
What it is and how it works
Adrabetadex is a cyclodextrin. Niemann-Pick disease type C1 is a rare neurodegenerative genetic disorder in which cholesterol and other lipids are not transported normally inside cells. The sources do not describe the mechanism of adrabetadex in detail or how it differs from existing treatments.
Pivotal trials
Phase 2/3 trial of adrabetadex in NPC1 (interrater reliability analysis)
- Design
- Multicenter, prospective, randomized, double-blind trial. This publication analyzed agreement between two independent blinded central raters scoring the Niemann-Pick type C1 Severity Scale from site-recorded clinical data.
- Patients
- 56 patients with NPC1.
- Compared with
- Not described in the source.
- Primary endpoint
- The trial's primary clinical end point was a composite four-item score from the severity scale. This publication's objective was interrater reliability of that scale.
Result
Average kappa coefficients ranged between 0.69 and 0.89, indicating good to very good agreement between raters. Rater score distributions were almost identical. Agreement varied widely between individual visits, and weighted kappa reduced this variability. The efficacy result of adrabetadex versus comparator is not reported in this source.
- Other results
- Not reported in the source.
- Safety in the trial
- Not reported in the source.
EvidencePulse™
Ask about Lembaz
The question that opens in EvidencePulse
How does Lembaz (adrabetadex) compare with the alternatives (Miglustat, Symptomatic and supportive care, Antiseizure medications) for a severe form of Niemann-Pick disease type C? Summarize head-to-head and indirect evidence, efficacy, safety and where each fits, with citations.
Ask in EvidencePulseFree to try, more with 2MM+.
Deep research is a core feature of 2MM Max.
Safety signals
There is no boxed warning. The sources supplied do not list warnings, precautions or adverse event data. Clinicians should read the full prescribing information before use.
What it competes with
Niemann-Pick disease type C is a rare, progressive neurodegenerative disease. Care is mainly supportive and aimed at symptoms. The sources supplied do not describe disease-specific therapies.
- MiglustatSubstrate reduction therapy used in some regions for neurological manifestations of Niemann-Pick disease type C.
- Symptomatic and supportive careIncludes management of seizures, movement problems, swallowing difficulty and other neurological symptoms.
- Antiseizure medicationsUsed to control seizures that occur as the disease progresses.
Bottom line for clinicians
Lembaz is intended for patients with a severe form of Niemann-Pick disease type C. The supplied publication concerns the reliability of the severity scale used in the phase 2/3 trial of 56 patients, not efficacy or safety outcomes. Review the full label and the primary trial results before treatment decisions.
Our coverage
We have not covered this drug yet.
Sources
- FDA list of novel approvals
- Farhat N, et al. Consistently High Agreement Between Independent Raters of Niemann-Pick Type C1 Clinical Severity Scale in Phase 2/3 Trial. Pediatr Neurol. 2022;127:32-38.
Dosing, contraindications and full warnings are in the prescribing information.
New FDA approvals in your inbox
The free 2 Minute Medicine Daily Brief: new approvals, landmark trials and the day's top studies, written by physicians.
Your subscription opens securely in a new tab.
Last updated November 19, 2026 by 2 Minute Medicine.
For healthcare professionals. A summary of public FDA documents and published trials, not medical advice. Check the full prescribing information before prescribing.